Gaush Meditech released a supplemental profit warning stating that preliminary unaudited figures point to 2026 first-half revenue of approximately RMB583.20 million to RMB607.00 million, down 7.1%–10.7% from RMB653.10 million in the same period of 2025.

The company reiterated that the factors outlined in its 23 July 2026 profit-warning announcement remain in effect, without providing additional detail in this update.

Management is still finalising the interim results for the six months ended 30 June 2026. The figures have neither been audited nor reviewed by the external auditors or the board’s audit committee. The full interim results are scheduled for release by end-August 2026.

Gaush Meditech advised shareholders and potential investors to exercise caution when dealing in its shares.